查詢結果分析
相關文獻
- Optimal Control of Blood Pressure Can Reverse Left Ventricular Hypertrophy in Uremic Hypertensive Hemodialysis Patients
- 運動後低血壓反應與血壓控制之探討
- 從JNCVI及UKPDS談第二型糖尿病的血壓控制
- 對於第2型糖尿病人嚴格控制血壓的省思
- 整體性介入措施對社區高血壓患者服藥遵從行為及血壓控制成效之探討
- 血壓控制機轉與運動
- 雌性素17β-estradiol對切除卵巢大白鼠之心臟血管功能的影響
- 幾丁質、幾丁聚醣生技產品與血壓控制
- 高血壓治療與左心室肥大復原之探討
- The Comparative Study of ECG Dignostic Criteria in Canine Concentric and Eccentric Ventricular Hypertrophy
頁籤選單縮合
題 名 | Optimal Control of Blood Pressure Can Reverse Left Ventricular Hypertrophy in Uremic Hypertensive Hemodialysis Patients=血壓控制良好可改善尿毒高血壓長期透析患者之左心室肥大 |
---|---|
作 者 | 吳三江; 林少琳; 吳展名; 鄭富榮; 蘇清蓉; | 書刊名 | The Kaohsiung Journal of Medical Sciences |
卷 期 | 15:2 1999.02[民88.02] |
頁 次 | 頁62-68 |
分類號 | 415.31 |
關鍵詞 | 血壓控制; 左心室肥大; 尿毒高血壓慢性透析患者; Ventricular hypertrophy; Hemodialysis; |
語 文 | 英文(English) |
中文摘要 | 尿毒症患者降壓效應是否可改善左心室肥大,仍無定論。我們收集39位尿毒高血壓長期透析患者 (男性 27 位,女性 12 位,平均年齡 58.3 歲),並以 M-mode 及 2-dimensional 及 Doppler 心臟超音波觀察經 12 個月高血壓治療之左心室功能及大小。高血壓治療使用藥物包括血管昇壓素轉換脢抑制劑、乙型交感神經阻斷劑、鈣離子拮抗劑。患者依據收縮壓下降超過 10 mmHg 以上與否區分為反應組及非反應組。 反應組有 26 位,非反應組有 13 位患者。 於治療前,36 位患有 (92%) 具左心室肥大及舒張性功能不良,3 位患者 (8%) 具收縮性功能不良。12 個月觀察結束後,25 位患者 (64%) 具左心室肥大,30 位患者 (77%) 具舒張性功能不良,2 位患者 (5%) 收縮性功能不良。整個觀察過程左心室質量從 203.63 ± 70.47g/m2 降至 178.57 ± 67.31 g/m2。左心室質量與收縮性血壓有關,但確與舒張性血壓無關。於反應組收縮壓 (從 153.91 ± 13.24 mmHg 降至 134.43 ± 14.21 mmHg,p<0.01),舒張壓 (從 90.39 ± 7.89mmHg 降至 79.98 ± 7.35mmHg,p<0.01) 經降壓治療後,呈現統計學上之意義,反應組且顯示明顯的左心室縮小 (左心室質量從 208.52 ± 72.03g/m2 降至 168.52 ± 55.53 g/m2,p<0.05)。但於非反應組卻無左心室縮小之現象 (治療前左心室質量 194.84 ± 64.36 g/m2,治療後 193.66 ± 77.67g/m2)。我們結論,血壓控制良好可改善尿毒高血壓慢性透析患者之左心室肥大。 |
英文摘要 | We investigated the effects of antihypertensive treatment on left ventricular hypertrophy (LVH) of long-term hemodialysis patients. In uremic patients, it is still controversial in antihypertensive effect to the regression of LVH. The left ventricular size and function of 39 uremic hypertensive long-term hemodialysis patients (27 men, 12 women, mean age 58.3) was evaluated with M-mode, 2-dimensional and Doppler echocardiography before, and 12 months after, the start of combined antihypertensive therapy. This therapy included angiotensin Ⅱ converting enzyme inhibitors, beta-blockers and calcium antagonists. Patients were classified as responders or nonresponders, depending upon whether their systolic blood pressure (SBP) decreased by more than 10 mmHg after antihypertensive treatment for 12 months. Before treatment, 36 (92%) patients and LVH and diastolic dysfunction and three (8%) had systolic dysfunction. At the end of 12 months, only 25 (64%) patients had LVH, 30 (77%) had diastolic dysfunction and 2(5%) had systolic dysfunction. Left ventricular mass index (LVMI) also decreased from 203.63 ± 70. 47 g/m2 to 178.57 ± 67.31 g/m2. LVMI correlated with systolic blood pressure (SBP) but did not correlate with diastolic blood pressure (DBP) . There were 26 responders and 13 non-responders. Among responders, both the SBP (153.91 ± 13.24 mmHg vs 134.43 ± 14.21mmHg, p<0.01) and DBP (90.39 ± 7.89 mmHg vs 79.98 ± 7.35 mmHg, p<0.01) decreased significantly after antihypertensive therapy. Responders also exhibited progressive regression of LVH (LVMI decreased significantly from 208.52 ± 72.03 g/m2 to 168.52 ± 55.53g/m2,p<0.05). However, LVH regression was not found in nonresponders (LVMI showed 194.84 ± 64.36 g/m2 vs 193.66 ± 77.67 g/m2). We conclude that good control of blood pressure can reverse LVH in hypertensive hemodialysis patients. |
本系統中英文摘要資訊取自各篇刊載內容。